Research & Development
Explore Life Science, Innovate Cancer Precision Therapy
Research Area

Cancer Precision Therapy

志健金瑞,APS,新药研发,医药研发,癌症肿瘤精准治疗
Genomic and other molecular analyses across many types of cancer have revealed a striking diversity of genomic aberrations, altered signaling pathways, and oncogenic processes, which provide the comprehensive view of cancer precision therapy and pancancer study. 2018, Cell

Kinase Inhibitors

志健金瑞,APS,新药研发,医药研发,癌症肿瘤精准治疗
Approximately 110 novel kinases are currently being explored as targets, with the approximately 45 targets of approved kinase inhibitors represent only about 30% of the human kinome, indicating that there are still substantial unexplored opportunities for this drug class. 2021, Nature review

Mutation Induced Resistance

志健金瑞,APS,新药研发,医药研发,癌症肿瘤精准治疗
Drug resistance occurs primarily through four main mechanisms. Acquired drug resistance mutations most commonly affect the binding of the drug to its target. 2021, Nature review
Pipeline

Based on APS’s independent Integrated Computational Chemical Biology (ICCB) drug development platform, APS focuses on a deep understanding of cancer genetics, protein structure and function, synthetic medicinal chemistry, experiment and Computation integrated verification technology. We are seeking to develop additional therapeutic areas and next-generation precision therapies that target genetic drivers of cancer.


志健金瑞,APS,新药研发,医药研发,癌症肿瘤精准治疗
Target
Program
Indication
Discovery
Preclinical
IND Enabling
Phase1
Phase2
Approved
Stage
APS03118
NSCLC, MTC, and other solid tumors
IND Approved by FDA and NMPA
Undisclosed
Multiple solid tumors
Lead Discovery/ Optimization
Undisclosed
Multiple solid tumors
Lead Discovery/ Optimization
Undisclosed
Multiple solid tumors
Lead Discovery/ Optimization
Undisclosed
Multiple solid tumors
Lead Discovery/ Optimization
Clinical Trials

A Phase 1/2, global multi-center clinical trial of APS03118 in RET positive NSCLC, MTC and other solid tumor patients is opening.


志健金瑞,APS,新药研发,医药研发,癌症肿瘤精准治疗

APS03118 global clinical study plan

志健金瑞,APS,新药研发,医药研发,癌症肿瘤精准治疗

APS is going to launch a global multi-center Phase I/II clinical trial (LASER)

志健金瑞,APS,新药研发,医药研发,癌症肿瘤精准治疗

APS is going to launch a China only Phase I clinical trial

Contact

Address

Office: Philadelphia, US

Office: Building 10-1, No.2 Jingyuan North Street, BDA, Beijing, China

Tel

+1-484-222-1342 +86-10-67860673

Mobile Mode
Copyright © 2022 All Rights Reserved Applied Pharmaceutical Science
Terms of Use

Loading...

Privacy policy

Loading...